Sugi Predict

Sugi Predict / Targets / KCNK9

KCNK9

Potassium channel subfamily K member 9 · Q9NPC2 · KCNK9 on Sugi Atlas →

44,272 patent compounds predicted against KCNK9, 29,115 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL221421 SCHEMBL221421 0.56 20/20
SCHEMBL13234 SCHEMBL13234 0.60 11/20
SCHEMBL259666 SCHEMBL259666 0.87 9/20
SCHEMBL76595 SCHEMBL76595 0.50 9/20
SCHEMBL259468 SCHEMBL259468 0.87 7/20
SCHEMBL677855 SCHEMBL677855 0.71 7/20
SCHEMBL113971 SCHEMBL113971 0.66 7/20
Flutolanil Flutolanil (SCHEMBL18555) 0.65 7/20
SCHEMBL259371 SCHEMBL259371 0.63 7/20
SCHEMBL259311 SCHEMBL259311 0.60 7/20
SCHEMBL8208 SCHEMBL8208 0.57 7/20
SCHEMBL528261 SCHEMBL528261 0.54 7/20
SCHEMBL396708 SCHEMBL396708 0.57 6/20
SCHEMBL259463 SCHEMBL259463 0.55 6/20
SCHEMBL533767 SCHEMBL533767 0.81 5/20
SCHEMBL394748 SCHEMBL394748 0.76 5/20
SCHEMBL259430 SCHEMBL259430 0.76 5/20
Mepronil Mepronil (SCHEMBL18447) 0.67 5/20
SCHEMBL259352 SCHEMBL259352 0.61 5/20
SCHEMBL676284 SCHEMBL676284 0.57 5/20

Clinical trials — most relevant to KCNK9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study PHASE4COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Sandostatine® LP and Hyperinsulinism PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk nanCOMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China nanCOMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects nanRECRUITING
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
Gene Study for Infantile Onset Diabetes nanUNKNOWN
Southeast Asian Brugada Syndrome Cohort nanUNKNOWN
Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies nanRECRUITING
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development nanCOMPLETED
The Genetic Basis of Atrial Fibrillation (AF) nanCOMPLETED
Genetic Study for Infantile Onset Diabetes Mellitus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNK9 binder may also engage these)

ProteinNameSimilarity
Q9JL58 — 1.000 Q9JL58 →
Q3LS21 — 1.000 Q3LS21 →
KCNK3 Potassium channel subfamily K member 3 0.999 landscape →
Q63ZI0 — 0.993 Q63ZI0 →
O35111 — 0.992 O35111 →
O00180 — 0.990 O00180 →
O17185 — 0.989 O17185 →
Q9JIS4 — 0.988 Q9JIS4 →
Q22271 — 0.988 Q22271 →
Q8R454 — 0.987 Q8R454 →
Q9ES08 — 0.987 Q9ES08 →
Q61056 — 0.987 Q61056 →
P19334 — 0.986 P19334 →
Q93380 — 0.986 Q93380 →
O62852 — 0.986 O62852 →
O54912 — 0.985 O54912 →
Q9M8S6 — 0.985 Q9M8S6 →
Q9QX29 — 0.985 Q9QX29 →
P51914 — 0.985 P51914 →
O95477 — 0.985 O95477 →
Q96L42 — 0.985 Q96L42 →
O54852 — 0.984 O54852 →
TRPC1 Short transient receptor potential channel 1 0.984 landscape →
KCNK10 Potassium channel subfamily K member 10 0.984 landscape →
KCNK2 Potassium channel subfamily K member 2 0.984 landscape →
S4R2P9 — 0.984 S4R2P9 →
O35119 — 0.984 O35119 →
P97414 — 0.984 P97414 →
Q6R5A3 — 0.984 Q6R5A3 →
TRPC4 Short transient receptor potential channel 4 0.984 landscape →